Protein-protein interaction disruption as a next-generation antithrombotic strategy.

Area of Science:

• Hemostasis and Thrombosis
• Drug Discovery
• Protein-Protein Interactions

Background:

• Thrombus formation relies on sequential protein-protein interactions (PPIs) for platelet activation and coagulation.
• Current antithrombotic therapies, while effective, are limited by bleeding risks due to systemic inhibition of essential hemostatic factors.

Purpose of the Study:

• To introduce a "thrombus assembly" framework for antithrombotic drug discovery.
• To explore targeting protein-protein interaction interfaces involved in pathologic clot formation.

Main Methods:

• Reviewing established and emerging PPIs in platelet adhesion, activation, and coagulation complex assembly.
• Analyzing therapeutic modalities for interface blockade, including antibodies, aptamers, peptides, and small molecules.
• Discussing assays that maintain the biological context of interface interactions.

Main Results:

• Protein-protein interaction (PPI) disruption offers a context-dependent approach to antithrombotic therapy.
• Interface blockade strategies, such as VWF A1-GPIbα and GPVI inhibition, show translational proof in humans.
• Targeting coagulation complex assembly and thrombin exosites presents opportunities beyond active-site inhibition.

Conclusions:

• Disrupting the interfaces that organize thrombus assembly provides a pathway to more selective antithrombotic agents.
• This approach holds promise for developing therapies with a reduced risk of bleeding complications.
• The review outlines a roadmap for next-generation antithrombotic drug development focused on interface disruption.